1 Age-Associated B cells predict impaired humoral immunity after COVID-19 2 vaccination in patients receiving immune checkpoint blockade

3

4 Juan Carlos Yam-Puc¹^{+*}, Zhaleh Hosseini¹[†], Emily C. Horner¹[†], Pehuén Pereyra Gerber^{2,3}[†], Nonantzin Beristain-Covarrubias¹[†], Robert Hughes¹[†], Maria Rust¹, Rebecca H. 5 Boston¹, Magda Ali¹, Edward Simmons-Rosello¹, Martin O'Reilly¹, Harry Robson¹, Lucy H. 6 7 Booth¹, Lakmini Kahanawita¹, Sofia Grigoriadou⁴, Andrea Correa-Noguera⁵, Lourdes Ceron-Gutierrez⁵, Thomas Mulroney¹, Aleksei Lulla⁶, Katrin Fischer⁶, Andrew Craxton¹, Georgina 8 S.F. Anderson¹, Xiao-Ming Sun¹, Anne Elmer⁷, Caroline Saunders⁷, Areti Bermperi⁷, Sherly 9 Jose⁷, Mike Chapman¹, Marion MacFarlane¹, Anne E. Willis¹, Kiran R. Patil¹, Florian 10 Hollfelder⁶, Marko Hyvönen⁶, CITIID-NIHR COVID-19 BioResource Collaboration, Sarah 11 Spencer¹, Emily Staples¹, Matthew S. Buckland^{4,5}, Rainer Döffinger⁸, Christine Parkinson^{8§}, 12 Sara Lear^{8§}, Nicholas J. Matheson^{2,3,,8,9§}, James E. D. Thaventhiran^{1,2,8§*}. 13

```
15 <sup>1</sup> Medical Research Council Toxicology Unit, School of Biological Sciences, University of
```

- 16 Cambridge, Cambridge, UK.
- ¹⁷ ² Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), University
- 18 of Cambridge, UK
- ³ Department of Medicine, University of Cambridge, Cambridge, UK
- ⁴ Department of Clinical Immunology, Barts Health, London, UK.
- ⁵ UCL GOSH Institute of Child Health Division of Infection and Immunity, Section of Cellular
- 22 and Molecular Immunology, London, UK.
- ⁶ Department of Biochemistry, University of Cambridge, Cambridge, UK
- 24 ⁷ NIHR Cambridge Clinical Research Facility
- 25 ⁸ Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK
- ⁹ NHS Blood and Transplant, Cambridge, UK
- 27
- 28 *†* These authors contributed equally
- 29 § These authors contributed equally
- 30 * Corresponding authors: jedt2@cam.ac.uk, jcy28@cam.ac.uk.
- 31
- 32 Key words: Inborn error of immunity (IEI), immune-checkpoint blockade, neutralising
- 33 antibodies, antigen-specific memory B cells, BNT162b2 vaccine, immunodeficiency, cancer
- 34
- 35 The authors declare no potential conflicts of interest.
- 36

37 Abstract

38 The effect of immune checkpoint blockade on COVID-19 immunity is unclear. In this study, 39 we determine whether immune checkpoint blockade expanded age-associated B cells 40 (ABCs) are similar to those present in other conditions, and whether they enhance or detract 41 from the COVID-19 vaccine responses. First, we use single cell RNA sequencing 42 (scRNAseq) to show that ABCs arising from distinct aetiologies have common transcriptional 43 profiles and may be further subdivided according to expression of genes associated with 44 different immune functions, including the autoimmune regulator (AIRE). Next, we perform 45 detailed longitudinal profiling of the COVID-19 vaccination response in patients. Finally, we 46 show that high pre-vaccination ABC frequency correlates with decreased levels of antigen-47 specific memory B cells, and reduced magnitude and longevity of neutralising capacity 48 against authentic SARS-CoV-2 virus. Expansion of ABCs is a biomarker for individuals with 49 cancer requiring additional or more frequent booster immunisation against COVID-19. 50

51 Introduction

52 Despite the success of mRNA-lipid nanoparticle (mRNA-LNP) COVID-19 vaccines in 53 reducing the risk of symptomatic infection, hospitalisation, and death(1,2), vaccinated 54 patients with cancer remain at increased risk of severe outcomes following SARS-CoV-2 55 infection(3). A cancer therapy that observational studies(4-6) suggests could improve 56 vaccine efficacy is immune checkpoint blockade (ICB). By targeting PD-1 and CTLA-4 57 checkpoints, ICB non-specifically promotes T cell responses, including those involved in 58 anti-viral and anti-cancer immunity. Furthermore, preclinical evidence indicates immune 59 checkpoint blockade can, via T and B cell interactions, enhance antibody responses(7,8). 60 The neutralising antibodies produced by the humoral response are a vital component of 61 vaccine protection as they inhibit viral replication in vitro and correlate with protection against 62 infection in vivo(9-11). However, complicating the positive potential of ICB for vaccine 63 enhancement, ICB induces the expansion of a B cell subset termed in other contexts Age-64 Associated B cells (ABCs)(12), which may have a confounding effect on humoral vaccine 65 responses.

67 ABCs comprise a naturally occurring population of antigen-experienced B cells which 68 expands continuously with age in healthy individuals but accumulates prematurely in people 69 with certain immune dyscrasias, autoimmunity, and/or infectious diseases(13). They have 70 also been termed CD11c⁺ B cells, CD11c⁺T-bet⁺ B cells, double negative 2 (DN2) B cells or 71 atypical memory B cells(13-17), and may additionally be generated by external 72 challenges(18,19), including COVID-19 infection and vaccination(20). Although ABCs are 73 associated with disease in autoimmunity, their role in vaccine immunity is uncertain. In mice, 74 these cells are required for optimal antibody responses following influenza vaccination(21), 75 possibly due to enhanced ability to present antigens to T cells relative to follicular B 76 cells(16,22). In patients with cancer treated with ICB, the expansion of ABCs precedes the 77 development of both antibody-mediated and non-antibody-mediated autoimmunity(12). This 78 is in keeping with their role in promoting antibody responses. However, we and others have 79 shown that expansion of ABCs is associated with antibody deficiency in specific cohorts of 80 patients with inborn errors of immunity (IEI)(23-26). These include patients with NFKB1 81 haploinsufficiency, in whom the genetic lesion leads predominantly to B cell-intrinsic 82 immunodeficiency(26), and patients with CTLA4 haploinsufficiency, in whom the genetic-83 lesion leads predominantly to a B cell-extrinsic functional T cell deficit (24,27). These 84 observations suggest two key questions: are the ABCs found in patients treated with ICB 85 equivalent to those found in other settings? And do these cells, when expanded through 86 distinct mechanisms, have a positive or negative effect on humoral vaccine responses?

⁶⁶

87

The increase in patients with cancer eligible to receive ICB treatment(28) and the survival benefit conferred by ICB treatment means that optimally protecting patients with cancer who are receiving these therapies from infection will be an increasing priority. Here, we answer the above questions regarding the characteristics and activity of ABCs in different patient groups as well as developing an understanding of the crosstalk between ICB and successful vaccination.

94

95 Results

96 ABCs arising from distinct aetiologies have common transcriptional profiles

97 We first assessed the similarities between ABCs from patients with different causes for ABC 98 expansion, using single cell RNA sequencing (scRNAseq). This included B cells from 99 healthy controls (HC, n=8), patients with cancer treated with ICB (ICB, n=8) and patients 100 with NFKB1 or CTLA4 haploinsufficiency (IEI, n=4), together with a published set of single B 101 cell transcriptomes from patients with SLE (n=3)(29). By focussing on patients with rare, 102 monogenic defects leading to well-characterised IEI, we were able to ensure that contrasting 103 B cell intrinsic (NFKB1) and extrinsic (CTLA4) aetiologies were included. Unsupervised 104 clustering of the 52,402 B cells, displayed in a uniform manifold approximation and 105 projection (UMAP) visualisation, revealed six clusters (Fig. 1a-c). Using CITE-seq, we 106 identified ABCs that had low CD21 and high CD11c surface protein expression, in keeping 107 with the definitions used in previous flow cytometry-based studies(12,26,30) (Supplementary 108 Fig. 1a-b). Cells were dispersed across all clusters regardless of the patient group or sex 109 from which they originated (Fig. 1b-d). ABC frequencies were higher in all patient groups 110 compared to healthy controls (Fig. 1d).

111

112 Distinct subsets of ABCs express genes associated with distinct immune function

113 The clustering and marker gene expression suggested that the ABC population can be 114 subdivided into "Classical ABCs", "Anergic ABCs" and "CD1c ABCs" (Fig. 1e). Classical 115 ABC frequencies were higher in females and patients with SLE (Fig. 1b-d and 116 Supplementary Fig. 1c-e). ABCs have been described as "anergic B cells" (31,32), 117 interestingly, anergic ABCs (expressing canonical genes associated with anergy, such as 118 EGR1 and NR4A1) clustered separately from Classical ABCs (Fig. 1a and Fig. 1e and 119 **Supplementary Table 1**), indicating heterogeneity within ABCs for this phenotype. Indeed, 120 many of the most differentially expressed genes in Classical ABCs were associated with 121 MHC class II-restricted antigen presentation (Fig. 1f). Gene ontology enrichment analysis 122 demonstrated selective upregulation of biological processes associated with professional

123 antigen presentation, such as antigen uptake, processing, class II presentation, and co-124 stimulation (**Fig. 1g** and **Supplementary Table 2**). This was specific for MHC class-II-125 restricted antigen presentation, as genes required for MHC class I-restricted antigen 126 presentation were instead differentially expressed in CD1c ABCs, relative to Classical ABCs 127 (Supplementary **Fig. 2**). This supports the functional separation of these two clusters, which 128 were less distinct on UMAP visualisation (**Fig. 1a**).

129

130 Upregulation of AIRE and its target genes is seen in Classical ABCs

131 We confirmed MHC-II antigen presentation related genes were amongst the most 132 differentially expressed genes of Classical ABCs (Fig. 2a and Supplementary Table 3). 133 Surprisingly, this analysis revealed the Autoimmune Regulator (AIRE) to be significantly 134 upregulated in Classical ABCs from all subject cohorts (Fig. 2a-b, Supplementary Fig. 3). 135 AIRE-expressing B lymphocytes were also in other clusters, albeit at a much lower 136 frequency (Fig. 2c). This is consistent with the accumulation of AIRE-expressing B cells in 137 the Classical ABC differentiation state during peripheral B cell development, rather than 138 selective upregulation of AIRE after ABC differentiation. Expression of a single gene in 139 3.85% of cells will make a negligible contribution to the UMAP clustering, therefore 140 enrichment of AIRE-expressing cells within the apex of the Classical ABC cluster 141 (Supplementary Fig. 3a) further supports the biological association of AIRE expression and 142 ABC differentiation. AIRE is a transcriptional regulator expressed in both the thymic 143 epithelium and thymic B cells(33,34), which increases expression of tissue-restricted 144 antigens (TRAs). TRA expression in the thymus is a central tolerance mechanism, whereby 145 stimulation of developing T cells by antigens usually expressed in non-thymic tissues directs 146 these cells away from fates with the potential for harmful self-antigen driven autoimmune 147 responses. Previous reports have suggested that AIRE is not functional in the small 148 proportion of peripheral lymphocytes in which it can be detected (35-37), although AIRE 149 function has never been assessed in ABCs (a peripheral B cell subset specifically 150 associated with autoimmune disease(16,38,39)). AIRE-expressing cells also upregulated a 151 set of genes previously defined as AIRE targets in thymic B cells(34) (Fig. 2d and 152 Supplementary Fig. 3). In addition, Classical ABCs upregulated HLA-G (Supplementary Fig. 153 2), a non-classical class I HLA molecule transactivated by AIRE in thymic epithelial cells(40). 154 Taken together, these data provide functional evidence of AIRE expression in Classical 155 ABCs. Further work will be necessary to evaluate if AIRE expression in ABCs leads to self-156 antigen expression and productive presentation that can initiate autoimmune responses.

157

ABC frequency predicts neutralising antibody response to COVID-19 vaccination

159 To investigate the impact of ABCs on mRNA-LNP vaccination, we next analysed the 160 immune response to the mRNA BNT162b2 COVID-19 vaccine in patients with variable 161 expansion of ABCs, including healthy controls (HC, n=10), patients with cancer treated with 162 ICB (ICB, n=19) and patients with NFKB1 or CTLA4 haploinsufficiency (IEI, n=9) (Fig. 3a 163 and Supplementary Table 4). All subjects were invited for blood sampling prior to their 164 second vaccine dose (day 0), then at early (day 8), mid (day 21) and late (day 105) time 165 points after this dose (Fig. 3a). Classical ABC frequencies prior to vaccination (day 0) were 166 determined by multicolour flow cytometry staining for CD11c and CD21 (Supplementary Fig. 167 4a) and found to be elevated in patients compared with healthy controls (Fig. 3b-c).

168

169 Serum reactivity against SARS-CoV-2 spike (S), receptor-binding domain (RBD) and 170 nucleocapsid (NCP) antigens was evaluated at day 21 after the second dose in the 171 diagnostic immunology laboratory. The majority of patients (18/19 ICB, 5/8 IEI) generated 172 IgG antibodies against S and RBD antigens (encoded by BNT162b2) at levels similar to the 173 healthy control group (Supplementary Fig. 4b). These responses were unlikely to reflect 174 previous natural infection with SARS-CoV-2, as patients did not have evidence of NCP 175 reactivity (not encoded by BNT162b2) (Supplementary Fig. 4b). The quality of the COVID-176 19-specific antibody response can be determined by measuring the capacity of serum to 177 neutralise authentic SARS-CoV-2 virus(41). Overall, most subjects displayed a rapid 178 increase in neutralising antibody titres, peaking early (day 8) after their second vaccine dose 179 (Fig. 3d and Supplementary Fig. 4c). By contrast, 5 patients (4 IEI and 1 ICB) failed to 180 develop detectable neutralising capacity at any time point, despite having detectable anti-S 181 antibodies. These patients are at greater risk of infection with SARS-CoV-2 and may be 182 susceptible to prolonged or refractory COVID-19(42,43).

183

184 Critically, the frequency of pre-vaccine ABCs was inversely correlated with neutralising 185 antibody titre at all timepoints (Fig. 3e), suggesting that ABCs predict both peak neutralising 186 capacity after vaccination, and the longevity of the neutralising antibody response. Indeed, at 187 day 105, 4/8 patients with IEI and 8/16 patients treated with ICB had neutralising antibody 188 titres which had fallen below the highest titre observed at day 0, compared with 0/7 HCs 189 (Fig. 3d). Individuals with neutralising capacity below this threshold showed higher 190 frequencies of ABCs than the individuals above it (**Fig. 3f**). Premature expansion of ABCs is 191 therefore seen both in patients with IEI and patients with cancer treated with ICB, and 192 (regardless of aetiology) correlates with a reduced ability to generate and maintain 193 neutralising antibody responses to COVID-19 vaccination.

Premature expansion of ABCs is associated with lower levels of antigen-specific memory B cells

197 Whilst circulating antibodies derived from plasma cells wane over time, long-lived 198 immunological memory can persist in expanded clones of antigen-specific memory B cells. 199 We therefore assessed the frequency and differentiation of circulating SARS-CoV-2 RBD-200 specific B cells elicited after the second dose of vaccine using multicolour flow cytometry 201 (Supplementary Fig. 5a). Strikingly, RBD-binding B cells were always significantly less 202 frequent in patients than in healthy controls (Fig. 4a-b and Supplementary Fig. 5B), and the 203 fraction of RBD-binding B cells amongst all CD19⁺ B cells correlated consistently with titres 204 of neutralising antibodies (Supplementary Fig. 5c). In addition, RBD-specific B cell 205 frequency immediately prior to the second vaccine dose correlated with neutralising capacity 206 at days 8 (peak response), 21 and 105 (Fig. 4c). This is consistent with a causal relationship 207 between the level of antigen-specific B cells prior to the second dose of vaccine, and the 208 magnitude and longevity of the neutralising antibody response. Furthermore, similar to 209 neutralising capacity, the levels of RBD-specific B cells at later timepoints could be predicted 210 by the frequency of ABCs at day 0 (Fig. 4d). Individuals with the highest frequencies of 211 ABCs showed reduced RBD-specific B cell differentiation (Supplementary Fig. 5c-d).

212

213 Finally, to analyse the cellular phenotype of rare RBD-binding B cells in a comprehensive, 214 unbiased way, we performed unsupervised clustering and UMAP visualisation of flow 215 cytometry data from all patients and HCs at all timepoints after vaccination (Fig. 4e). RBD-216 binding B cells from both patients and HCs were observed within clusters of memory B cells 217 and plasmablasts (Fig. 4f), suggesting a quantitative reduction rather than qualitative 218 difference in the humoral response. Across all participants, the proportion of RBD-specific 219 cells expressing plasmablast markers peaked at day 8, whilst those expressing memory B 220 cell makers peaked a day 21 (Fig. 4g). Differentiation of antibody-producing cells therefore 221 occurs contemporaneously with peak neutralisation capacity (day 8). Since increased 222 antibody production cannot be driven by the proliferation of terminally differentiated (non-223 dividing) plasma cells, a sizeable contribution to the neutralising antibody response after the 224 second dose of vaccine is likely the result of this memory B cell proliferation and 225 differentiation. Taken together, our data therefore suggest that premature expansion of 226 ABCs negatively impacts all aspects of the humoral immune response to COVID-19 227 vaccination.

228

229 Discussion

230 While the specific causal mechanism for ABC expansion in any single older patient (to which 231 polygenic risk alleles, ageing, therapy and obesity can all contribute) is unknown, in young 232 patients with ultra-rare monogenic inherited disease, expansion is caused by the specific 233 gene disrupted. Our analysis of 4 different patient groups: healthy controls, patients with 234 cancer treated with ICB, patients with autoimmune SLE, and patients with two distinct IEI 235 (CTLA haploinsufficiency and NFKB1 haploinsufficiency) demonstrates a homogeneity of the 236 ABC differentiation states irrespective of the specific cause. Therefore, the pathological 237 consequence of expanded ABCs is likely related to their increased frequency rather than an 238 inherent difference in these cells from patients with distinct diseases. Additionally, the finding 239 of AIRE and tissue restricted antigen expression within a small subset of Classical ABCs, 240 cells that transcriptionally appear as professional antigen presenting cells could provide a 241 mechanistic link between the expansion of these cells and the autoimmune toxicity 242 associated with ICB therapy.

243

244 Most clinically relevant, however, is our finding that patients with expanded ABCs have a 245 reduced B cell vaccine response, leading to reduced neutralisation capacity and reduced 246 memory B cell formation. Since memory B frequency before vaccination correlates with the 247 subsequent neutralisation response to immunisation, this predicts that there will be reduced 248 neutralisation capacity to subsequent booster immunisation. Consequently, patients with 249 expanded ABCs will require more frequent booster immunisation to achieve an equal level of 250 longitudinal B cell immune protection. Overall, these results place ABC frequency as a 251 predictive biomarker for reduced vaccine protection that could guide booster vaccination 252 schedules for patients at risk of breakthrough infection.

253

254 Methods

255 Patient recruitment and ethics

Enrolment of patients into this study was based on the deficiency of particular genes of interest (IEI: CTLA4, LRBA, NFkB1, NFkB2) or clinical diagnostics (ICB, n = 19), whilst healthy controls for this study were enrolled based on their clinical healthy status (n = 10). Sample-size calculation was limited due to IEI patients in the study (n = 9) reflect a rare population of individuals within the general population that we were able to recruit (Supplementary Table 4).

The research was conducted in accordance with the principles of Good Clinical Practice and following granted protocols of the National Institute for Health and Care Research (NIHR) Bioresource of England or granted protocols of the Barts and the London Immunology Registry, United Kingdom. Samples were collected with the written informed consent of all

study participants under the NIHR BioResource - Research Tissue Bank (NBR-RTB) ethics
(REC:17/EE/0025) or under the Barts and the London Immunology Registry (REC:
11/LO/1689), United Kingdom. Clinical data were collected by Clinical Immunology
Consultants at Cambridge University Hospital and Bart's Health at London, United Kingdom
via the Electronic Healthcare Record (Epic), or direct patient contact.

The patients and healthy controls were consented under the East of England Cambridge South National research ethics committee (REC) reference 13/EE/0325 or Barts and the London Immunology Registry (REC: 11/LO/1689), United Kingdom.

274

275 Blood donation and separation

276 Patients and controls gave voluntary blood samples prior to second dose and at early (day 277 8), mid (day 21) and late (day 105) timepoints following their second BNT162b2 vaccine. 278 Where sample size of individual assays was not the same as the total sample size, this was 279 because there was no sample collection at those specific time points. Samples may have 280 also been excluded if there was serological evidence of prior exposure to SARS-COV-2. 281 Peripheral blood samples were acquired in either lithium heparin or serum separating tubes. 282 Peripheral blood mononuclear cells (PBMCs) were isolated by a density gradient 283 centrifugation protocol and stored at -80°C for up to a week before being transferred to liquid 284 nitrogen until use. Whilst serum tubes were centrifuged to separate serum from cell pellet 285 before being aliquoted and stored at -80°C until use.

286

287 Single cell library preparation and sequencing

288 Frozen PBMCs were thawed and B cell population was enriched using magnetic separation 289 (Miltenyi 130-101-638). Samples were next labelled with oligonucleotide-tagged antibodies 290 against CD11c, CD21, CD27 and CD85j (TotalSeq, BioLegend). After labelled, cell counts 291 were adjusted to 1,035 cells per microlitre before being loaded onto a Chromium Next GEM 292 chip K (10X Genomics, 2000182) for the subsequent library's construction according to 293 Single cell 5' v2 protocol (CG000330 RevA, 10X Genomics). The library was quality 294 controlled by Agilent 4150 TapeStation and quantified by RT-PCR using the KAPA library 295 quantification kit for Illumina platforms (Roche, KK4824). Samples were sequenced on an 296 Illumina NovaSeg with a sequencing depth of at least 50, 000 reads per cell.

297

298 Software versions

Single cell data was analysed using Cell Ranger software version 6.1.1, citeseq version
1.5.0, R version 4.0.3 and R packages (Seurat 4.1.0, SeuratObject 4.0.4, Scuttle 1.0.4,
rstatix 0.7.0, tidyverse 1.3.0 and dplyr 1.0.8). Flow cytometry data and antibody titres were

analysed using FlowJo 10.7.1 and GraphPad Prism 9.1.2 (225), respectively. Figures were
produced using ggplot2 3.3.5, gridExtra 2.3, ComplexHeatmap 2.6.2, Nebulosa 1.0.2,
RColorBrewer 1.1-2, ggrepel 0.9.1, ggpubr 0.4.0, scales 1.1.1, showtext 0.9-5 in R and
GraphPad Prism 9.1.2 (225) and FlowJo 10.7.1.

306

307 Preprocessing of scRNA-seq data

308 Raw FASTQ files of the gene expression library were analysed using 10x Genomics Cell 309 Ranger software v.6.1.1[1] and aligned to the GRCh38 genome provided by Cell Ranger. All 310 Ig V, D, J and constant genes as well as TCR genes were deleted from the dataset so that 311 downstream analysis is not affected by highly variable clonotype genes. For the 312 quantification of antibody derived tags (ADT) and oligo hashtags, citeseq pipeline v.1.5.0[2] 313 was used. The generated hashtag count matrices as well as raw gene expression count 314 matrices were then used as inputs for the Seurat package v.4.1.0[3] in R v.4.0.3. Seurat 315 objects were created from the corresponding transcript count matrices. ADT assays were 316 added using CreateAssayObject function of Seurat to include expression levels of surface 317 proteins. Samples were then demultiplexed using HTODemux function. Doublets and cells 318 with no assigned hashtag were removed from objects for further analysis. Scuttle package 319 v.1.0.4[4] was used for quality control. 3 x Median absolute deviation (MAD) was considered 320 as the threshold for quality control; number of features and number of read counts were 321 filtered from both sides, whereas percentage of mitochondrial genes was filtered from upper 322 side. The samples were log-normalized for further differential expression analysis. Before 323 integrating all objects, they were normalized based on regularized negative binomial 324 regression using the SCTransform function of the Seurat package, regressing out for cell 325 cycle scores, number of counts and percentage of mitochondrial genes. The objects were 326 then integrated using the integration protocol of the Seurat package to perform batch effect 327 correction. The objects used for integration include: four groups of healthy controls each 328 having two subjects (total of 26900 cells in the final dataset), one group of IEI patients (5345) 329 cells in the final dataset) and two groups of ICB patients (total of 9751 cells in the final 330 dataset) each having four subjects, and SLE patients with 3 subjects (10406 cells in the final 331 dataset).

332

333 SLE data

Data of SLE patients from Bhamidipati et al [5] was downloaded from GSE163121,
 reprocessed and integrated with other objects using the same procedure as described
 above.

338 Clustering of data

339 Principal component analysis (PCA) was performed on the integrated object to reduce the 340 dimensionality of the dataset. First, clustering was done using 30 principal components 341 (PCs) and resolution parameter of 0.1. Clusters with a high expression of non-B cell markers 342 were removed from the dataset. After deletion of all non-B cells, the dataset consists of 343 52402 cells. PCs were calculated in the new dataset and unsupervised clustering was 344 performed using 20 PCs and resolution parameter of 1.4. Cluster markers were calculated 345 with the default parameters of the FindMarkers function. Clusters with similar markers were 346 manually merged. Final clusters were labelled based on the differentially expressed genes in 347 each cluster.

348 Gene ontology enrichment analysis

349 Gene ontology [6, 7] enrichment analysis was performed via PANTHER [8] from 350 http://www.geneontology.org using the list of significantly upregulated genes from classical

- 351 ABC cluster (Average log2 fold change > 0.25 and percent expressed in each group > 0.25).
- 352

353 Geneset Scores

A list of 74 Aire-induced genes were obtained from Yamano et al., [9] after converting mouse
 gene IDs to human gene IDs. For calculating gene set score for each cell, AddModuleScore
 function from Seurat package was used.

357

358 Kernel density estimation of gene expression

Nebulosa package v 1.0.2 [10] was used for calculating and plotting gene-weighted densityestimation of AIRE expression.

361

362 SARS-CoV-2 serology

363 A Luminex bead-based immunoassay was used to guantify specific antibodies to full-length 364 trimeric spike (S), spike receptor binding domain (RBD) and nucleocapsid (NCP) of SARS-365 CoV-2 as previously described [11, 12]. Briefly, a multiplex assay was established by 366 covalently coupling recombinant SARS-CoV-2 proteins to distinct carboxylated bead sets 367 (Luminex, Netherlands). The S protein used here was the S-R/PP described in Xiong et al 368 [11], and the RBD protein was described by Stadlbauer et al [13]. The NCP protein used is a 369 truncated construct of the SARS-CoV-2 NCP protein comprising residues 48-365 (both 370 ordered domains with the native linker) with an N terminal uncleavable hexahistidine tag. 371 NCP was expressed in E. Coli using autoinducing media for 7h at 37°C and purified using 372 immobilised metal affinity chromatography (IMAC), size exclusion and heparin 373 chromatography. The S-, RBD- and NCP-coupled bead sets were incubated with patient

sera at 3 dilutions (1/100, 1/1000, 1/10000) for 1 h in 96-well filter plates (MultiScreen HTS; Millipore) at room temperature in the dark on a horizontal shaker. After washes, beads were incubated for 30 min with a PE-labeled anti-human IgG-Fc antibody (Leinco/Biotrend), washed as described above, and resuspended in 100 µl PBS/ Tween. Antibody-specific binding was interpreted using Exponent Software V31 software on the Luminex analyzer (Luminex / R&D Systems) and reported as mean fluorescence intensity (MFI). The diagnostic thresholds used adhered to UK national guidelines.

381

382 Neutralising antibodies to SARS-CoV-2

The SARS-CoV-2 used in this study was a wildtype (lineage B) virus (SARS-CoV-2/human/Liverpool/REMRQ0001/2020), a kind gift from Ian Goodfellow (University of Cambridge), isolated early in the COVID-19 pandemic by Lance Turtle (University of Liverpool) and David Matthews and Andrew Davidson (University of Bristol) [14-16] from a patient on the Diamond Princess cruise ship. Sera were heat-inactivated at 56°C for 30 mins before use, and neutralising antibody titres at 50% inhibition (NT50s) measured as previously described [17, 18].

In brief, luminescent HEK293T-ACE2-30F-PLP2 reporter cells (clone B7) expressing SARS-CoV-2 Papain-like protease-activatable circularly permuted firefly luciferase (FFluc) were seeded in flat-bottomed 96-well plates. The next day, SARS-CoV-2 viral stock (MOI=0.01) was pre-incubated with a 3-fold dilution series of each serum for 2 h at 37°C, then added to the cells. 16 h post-infection, cells were lysed in Bright-Glo Luciferase Buffer (Promega) diluted 1:1 with PBS and 1% NP-40, and FFluc activity measured by luminometry. Experiments were conducted in duplicate.

To obtain NT50s, titration curves were plotted as FFluc vs log (serum dilution), then analysed by non-linear regression using the Sigmoidal, 4PL, X is log(concentration) function in GraphPad Prism. NT50s were reported when (1) at least 50% inhibition was observed at the lowest serum dilution tested (1:20), and (2) a sigmoidal curve with a good fit was generated. For purposes of visualisation and ranking, samples for which visual inspection of the titration curve indicated inhibition at low dilutions, but which did not meet criteria (1) and (2) above, were assigned an arbitrary NT50 of 4.

World Health Organisation International Standard 20/136 (WHO IS 20/136) has an NT50 of 1967 against wildtype SARS-CoV-2 when measured in this assay. This standard comprises pooled convalescent plasma obtained from 11 individuals which, when reconstituted, is assigned an arbitrary neutralising capacity of 1000 IU/ml against early 2020 SARS-CoV-2 isolates [19]. NT50s from this study may therefore be converted to IU/ml using a calibration

409 factor of 1000/1967 (0.51), with a limit of quantitation of 10.2 IU/ml (corresponding to an 410 NT50 of 20).

411

412 Flow cytometric analysis of B cells

413 Frozen PBMCs were thawed and stained with B cell panel antibody cocktail (Supplementary 414 Table 5). All samples were acquired on the BD LSRFortessa using FACSDIVA software 415 (BD-Biosciences). FCS files were exported and analysed using FlowJo v10.7.2 (BD-416 Additionally, a uniform manifold approximation and projection Biosciences) software. 417 (UMAP) algorithm for dimensional reduction was performed on a concatenated FCS file 418 comprising events from the CD19+ gate from HC, IEI and ICB samples analysed, utilizing 419 the UMAP FlowJo plugin (v3.1). The composite samples were gated as indicated on 420 Supplementary Fig. 2 for RBD+ B cell identification and then overlaid by study group in the 421 UMAP generated, for additional visualisation. XShift (v1.4.1) and ClusterExplorer (1.5.15) 422 plugins were used for unsupervised cluster generation and exploration, respectively. Class-423 switched memory B cells and plasmablasts/plasma cells were selected based on the 424 expression of CD19+IgD-IgM-CD38-CD27+ and CD19+IgD-IgM-CD38+/highCD27+/high, 425 respectively.

426

427 **RBD tetramer production**

428 SARS-CoV-2 RBD was expressed with N-terminal fusion of His-Zbasic-TEV module (8×His 429 tag, Zbasic domain [20] and TEV protease cleavage site) and C-terminal Avi-tag in 430 BL21(DE3) cells (Novagen) cultured in 2xYT media at 37°C. RBD containing inclusion 431 bodies were isolated and solubilised. The denatured protein was first purified by immobilized 432 metal affinity chromatography using PureCube Ni-NTA resin, eluted and refolding was 433 allowed to proceed for 72 hours at 4°C. N-terminal fusion tag was cleaved off by NHis-434 TEVpro (produced in-house). Biotinylation of the RBD protein was carried out using 5 mM 435 MgCl2, 2 mM ATP, 150 µM biotin and 50 µg/ml of biotin ligase BirA-CHis (produced in-436 house). The excess of biotinylated RBD protein was then incubated with 0.5 mg/ml of 437 fluorescently labelled Streptavidin (BioLegend) for 1 hour at room temperature and, finally, 438 RBD-Streptavidin complexes were separated by size exclusion chromatography using a 439 Superdex 200 Increase 10/300 GL column (Cytiva). The RBD-Streptavidin complexes were 440 then analysed by SDS-PAGE.

441

442 Statistical analysis

443 Statistical analysis for FACS and serology data was performed using GraphPad Prism 444 v9.1.1 (GraphPad Prism Software Inc). Two-tailed non-parametric Mann Whitney tests were

445 used to determine differences between groups. For multiple comparisons ANOVA with 446 Tukey's multiple comparisons test was used. Associations were calculated using two-tailed 447 Spearman's rank correlations and results are shown with linear trend levels. For the single 448 cell data, statistical significance for paired comparisons were performed using Wilcoxon rank 449 sum test in R.

450

451 Data and code availability

- 452 Sequencing data have been deposited in the Gene Expression Omnibus database [GEO: in
- 453 preparation]. Additional information and materials and all codes for scRNA-seq analysis will
- 454 be made available upon request.
- 455

456 References

 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384(5):403-16 doi 10.1056/NEJMoa2035389. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383(27):2603-15 doi 10.1056/NEJMoa2034577. Schmidt AL, Labaki C, Hsu CY, Bakouny Z, Balanchivadze N, Berg SA, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol 2022;33(3):340-6 doi 10.1016/j.annonc.2021.12.006. Monin L, Laing AG, Munoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22(6):765-78 doi 10.1016/S1470-2045(21)00213-8. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.cell.2021.06.002. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK,
 doi 10.1056/NEJMoa2035389. doi 10.1056/NEJMoa2035389. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, <i>et al.</i> Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383(27):2603-15 doi 10.1056/NEJMoa2034577. Schmidt AL, Labaki C, Hsu CY, Bakouny Z, Balanchivadze N, Berg SA, <i>et al.</i> COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol 2022;33(3):340-6 doi 10.1016/j.annonc.2021.12.006. Monin L, Laing AG, Munoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, <i>et al.</i> Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22(6):765-78 doi 10.1016/S1470- 2045(21)00213-8. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, <i>et al.</i> Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, <i>et al.</i> Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, <i>et al.</i> CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021
 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383(27):2603-15 doi 10.1056/NEJMoa02034577. Schmidt AL, Labaki C, Hsu CY, Bakouny Z, Balanchivadze N, Berg SA, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol 2022;33(3):340-6 doi 10.1016/j.annonc.2021.12.006. Monin L, Laing AG, Munoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22(6):765-78 doi 10.1016/S1470- 2045(21)00213-8. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. Edara VV, Lai L, Sahoo MK, Flo
 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383(27):2603-15 doi 10.1056/NEJMoa2034577. 3. Schmidt AL, Labaki C, Hsu CY, Bakouny Z, Balanchivadze N, Berg SA, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol 2022;33(3):340-6 doi 10.1016/j.annonc.2021.12.006. 4. Monin L, Laing AG, Munoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22(6):765-78 doi 10.1016/S1470- 2045(21)00213-8. 5. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncl.2021.2675. 6. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.021.06.002. 7. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. 8. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. 8. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):12
 2020;383(27):2603-15 doi 10.1056/NEJMoa2034577. 3. Schmidt AL, Labaki C, Hsu CY, Bakouny Z, Balanchivadze N, Berg SA, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol 2022;33(3):340-6 doi 10.1016/j.annonc.2021.12.006. 4. Monin L, Laing AG, Munoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22(6):765-78 doi 10.1016/S1470- 2045(21)00213-8. 5. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, et al. Serologic Status and Toxic Effects of the SARS-COV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. 6. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. 7. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. 8. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. 9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/20
 Schmidt AL, Labaki C, Hsu CY, Bakouny Z, Balanchivadze N, Berg SA, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol 2022;33(3):340-6 doi 10.1016/j.annonc.2021.12.006. Monin L, Laing AG, Munoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22(6):765-78 doi 10.1016/S1470- 2045(21)00213-8. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. Ldara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 465 COVID-19 vaccination and breakthrough infections in patients with cancer. Ann 466 Oncol 2022;33(3):340-6 doi 10.1016/j.annonc.2021.12.006. 477 4. Monin L, Laing AG, Munoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, 478 Alaguthurai T, <i>et al.</i> Safety and immunogenicity of one versus two doses of the 479 COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a 470 prospective observational study. Lancet Oncol 2021;22(6):765-78 doi 10.1016/S1470- 471 2045(21)00213-8. 472 5. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, 473 Shachor-Meyouhas Y, <i>et al.</i> Serologic Status and Toxic Effects of the SARS-CoV-2 474 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 475 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. 476 6. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, <i>et al.</i> 478 Seroconversion rates following COVID-19 vaccination among patients with cancer. 478 Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. 479 7. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell 480 Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 481 10.1016/j.immuni.2018.06.012. 482 8. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, <i>et al.</i> 483 CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of 484 CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 485 10.1073/pnas.1414576112. 486 9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> 487 Neutralizing antibody levels are highly predictive of immune protection from 488 symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 489 10.1038/s41591-021-01377-8. 490 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- 491 induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. 492 bioRxiv 2021 doi 10.1101/2021.05.09.4
 Oncol 2022;33(3):340-6 doi 10.1016/j.annonc.2021.12.006. Monin L, Laing AG, Munoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, <i>et al.</i> Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22(6):765-78 doi 10.1016/S1470- 2045(21)00213-8. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, <i>et al.</i> Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. Thakkar A, Gonzalez-Lugo DJ, Goradia N, Gali R, Shapiro LC, Pradhan K, <i>et al.</i> Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, <i>et al.</i> CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 Monin L, Laing AG, Munoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22(6):765-78 doi 10.1016/S1470- 2045(21)00213-8. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 Alaguthurai T, <i>et al.</i> Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22(6):765-78 doi 10.1016/S1470- 2045(21)00213-8. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, <i>et al.</i> Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, <i>et al.</i> Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, <i>et al.</i> CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22(6):765-78 doi 10.1016/S1470- 2045(21)00213-8. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, <i>et al.</i> Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, <i>et al.</i> Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, <i>et al.</i> CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 prospective observational study. Lancet Oncol 2021;22(6):765-78 doi 10.1016/S1470-2045(21)00213-8. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. IO. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1011/2021.05.09.443299.
 2045(21)00213-8. 2045(21)00213-8. 472 5. Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, <i>et al.</i> Serologic Status and Toxic Effects of the SARS-CoV-2 474 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. 476 6. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, <i>et al.</i> 477 Seroconversion rates following COVID-19 vaccination among patients with cancer. 478 Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. 479 7. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell 480 Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 481 10.1016/j.immuni.2018.06.012. 482 8. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, <i>et al.</i> 483 CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of 484 CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 485 10.1073/pnas.1414576112. 486 9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> 487 Neutralizing antibody levels are highly predictive of immune protection from 488 symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 489 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- 490 induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. 492 bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, <i>et al.</i> Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, <i>et al.</i> Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, <i>et al.</i> CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 Shachor-Meyouhas Y, et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. 6. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. 7. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. 8. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. 9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. 6. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, <i>et al.</i> Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. 7. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. 482 8. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, <i>et al.</i> CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. 486 9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. 490 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 2021;7(10):1507-13 doi 10.1001/jamaoncol.2021.2675. 6. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, <i>et al.</i> Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. 7. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. 8. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, <i>et al.</i> CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. 9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. 490 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant.
 Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, <i>et al.</i> Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, <i>et al.</i> CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 477 Seroconversion rates following COVID-19 vaccination among patients with cancer. 478 Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. 479 7. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell 480 Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 481 10.1016/j.immuni.2018.06.012. 482 8. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, et al. 483 CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of 484 CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 485 10.1073/pnas.1414576112. 486 9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. 487 Neutralizing antibody levels are highly predictive of immune protection from 488 symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 490 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine- 491 induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. 492 bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 Cancer Cell 2021;39(8):1081-90 e2 doi 10.1016/j.ccell.2021.06.002. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 Arigon 7. Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. 8. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. 9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 Positioning and Function. Immunity 2018;49(2):264-74 e4 doi 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 10.1016/j.immuni.2018.06.012. Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, <i>et al.</i> CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 Wang CJ, Heuts F, Ovcinnikovs V, Wardzinski L, Bowers C, Schmidt EM, <i>et al.</i> CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 10.1073/pnas.1414576112. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 483 CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of 484 CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 485 10.1073/pnas.1414576112. 486 9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> 487 Neutralizing antibody levels are highly predictive of immune protection from 488 symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 489 10.1038/s41591-021-01377-8. 490 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- 491 induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. 492 bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 484 CD28 engagement. Proc Natl Acad Sci U S A 2015;112(2):524-9 doi 485 10.1073/pnas.1414576112. 486 9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> 487 Neutralizing antibody levels are highly predictive of immune protection from 488 symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 489 10.1038/s41591-021-01377-8. 490 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- 491 induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. 492 bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 10.1073/pnas.1414576112. 486 9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> 487 Neutralizing antibody levels are highly predictive of immune protection from 488 symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 489 10.1038/s41591-021-01377-8. 490 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- 491 induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. 492 bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 486 9. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, <i>et al.</i> 487 Neutralizing antibody levels are highly predictive of immune protection from 488 symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 489 10.1038/s41591-021-01377-8. 490 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- 491 induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. 492 bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 487 Neutralizing antibody levels are highly predictive of immune protection from 488 symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 489 10.1038/s41591-021-01377-8. 490 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- 491 induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. 492 bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11 doi 10.1038/s41591-021-01377-8. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 10.1038/s41591-021-01377-8. 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 490 10. Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, <i>et al.</i> Infection and vaccine- 491 induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. 492 bioRxiv 2021 doi 10.1101/2021.05.09.443299.
 induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv 2021 doi 10.1101/2021.05.09.443299.
492 bioRxiv 2021 doi 10.1101/2021.05.09.443299.
493 11. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, <i>et al.</i>
494 Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical
495 trial. Science 2022 :375(6576):43-50 doi 10.1126/science.abm3425.
496 12. Das R. Bar N. Ferreira M. Newman AM, Zhang L. Bailur JK. <i>et al.</i> Early B cell
497 changes predict autoimmunity following combination immune checkpoint blockade. J
498 Clin Invest 2018 :128(2):715-20 doi 10.1172/JCI96798.
499 13. Cancro MP. Age-Associated B Cells. Annu Rev Immunol 2020 :38:315-40 doi
500 10.1146/annurev-immunol-092419-031130.
501 14. Hao Y. O'Neill P. Naradikian MS. Scholz JL. Cancro MP. A B-cell subset uniquely
502 responsive to innate stimuli accumulates in aged mice. Blood 2011 :118(5):1294-304
503 doi 10.1182/blood-2011-01-330530.

504	15.	Kim CC, Baccarella AM, Bayat A, Pepper M, Fontana MF. FCRL5(+) Memory B
505		Cells Exhibit Robust Recall Responses. Cell Rep 2019;27(5):1446-60 e4 doi
506		10.1016/j.celrep.2019.04.019.
507	16.	Rubtsov AV, Rubtsova K, Fischer A, Meehan RT, Gillis JZ, Kappler JW, et al. Toll-
508		like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is
509		important for the development of autoimmunity. Blood 2011 ;118(5):1305-15 doi
510		10.1182/blood-2011-01-331462.
511	17.	Stewart A, Ng JC, Wallis G, Tsioligka V, Fraternali F, Dunn-Walters DK. Single-Cell
512		Transcriptomic Analyses Define Distinct Peripheral B Cell Subsets and Discrete
513		Development Pathways. Front Immunol 2021;12:602539 doi
514		10.3389/fimmu.2021.602539.
515	18.	Myles A, Sanz I, Cancro MP. T-bet(+) B cells: A common denominator in protective
516		and autoreactive antibody responses? Curr Opin Immunol 2019;57:40-5 doi
517		10.1016/j.coi.2019.01.002.
518	19.	Rubtsov AV, Marrack P, Rubtsova K. T-bet expressing B cells - Novel target for
519		autoimmune therapies? Cell Immunol 2017;321:35-9 doi
520		10.1016/j.cellimm.2017.04.011.
521	20.	Pape KA, Dileepan T, Kabage AJ, Kozysa D, Batres R, Evert C, et al. High-affinity
522		memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and
523		atypical memory B cells than those primed by mRNA vaccines. Cell Rep
524		2021 ;37(2):109823 doi 10.1016/j.celrep.2021.109823.
525	21.	Johnson JL, Rosenthal RL, Knox JJ, Myles A, Naradikian MS, Madej J, et al. The
526		Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue
527		Distributions and Antibody Specificities in Mice and Humans. Immunity
528		2020 ;52(5):842-55 e6 doi 10.1016/j.immuni.2020.03.020.
529	22.	Rubtsov AV, Rubtsova K, Kappler JW, Jacobelli J, Friedman RS, Marrack P. CD11c-
530		Expressing B Cells Are Located at the T Cell/B Cell Border in Spleen and Are Potent
531	• •	APCs. J Immunol 2015 ;195(1):71-9 doi 10.4049/jimmunol.1500055.
532	23.	Gamez-Diaz L, August D, Stepensky P, Revel-Vilk S, Seidel MG, Noriko M, et al.
533		The extended phenotype of LPS-responsive beige-like anchor protein (LRBA)
534		deficiency. J Allergy Clin Immunol 2016;137(1):223-30 doi 10.101 c /(1):223-30 doi
535	24	10.1016/j.jaci.2015.09.025.
536	24.	Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DI, et al. Immune
53/		dysregulation in human subjects with heterozygous germline mutations in C1LA4.
538	25	Science 2014;345(6204):1625-7 doi 10.1126/science.1255904.
539	23.	Schwad C, Gaorysch A, Olorich P, Patino V, Warnatz K, Wolli D, et al. Phenotype,
540		subjects. L Allergy Clin Instrumed 2018:142(6):1022.46 doi:
541 542		subjects. J Anergy Chin Immunol 2018 ;142(6):1932-40 doi
542 543	26	Tuiinanburg D Lango Allan H Burns SO Graana D Jansan MH Stanlas E <i>at al</i>
545	20.	Loss of function nuclear factor kannaB subunit 1 (NEKB1) variants are the most
544		common monogenic cause of common variable immunodeficiency in Europeans. I
546		Allergy Clin Immunol 2018 :142(4):1285-96 doi 10 1016/i jaci 2018 01 039
540 547	27	Schubert D Bode C Kenefeck R Hou TZ Wing IB Kennedy A <i>et al</i> Autosomal
548	27.	dominant immune dysregulation syndrome in humans with CTLA4 mutations Nat
549		Med 2014 :20(12):1410-6 doi 10.1038/nm.3746.
550	28.	Haslam A. Gill J. Prasad V. Estimation of the Percentage of US Patients With Cancer
551		Who Are Eligible for Immune Checkpoint Inhibitor Drugs. JAMA Netw Open
552		2020 ;3(3):e200423 doi 10.1001/jamanetworkopen.2020.0423.

553	29.	Bhamidipati K, Silberstein JL, Chaichian Y, Baker MC, Lanz TV, Zia A, et al. CD52
554		Is Elevated on B cells of SLE Patients and Regulates B Cell Function. Front Immunol
555		2020 ;11:626820 doi 10.3389/fimmu.2020.626820.
556	30.	Schwab C, Gabrysch A, Olbrich P, Patino V, Warnatz K, Wolff D, et al. Phenotype,
557		penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient
558		subjects. J Allergy Clin Immunol 2018 doi 10.1016/j.jaci.2018.02.055.
559	31.	Isnardi I, Ng YS, Menard L, Meyers G, Saadoun D, Srdanovic I, et al. Complement
560		receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive
561		clones. Blood 2010 ;115(24):5026-36 doi 10.1182/blood-2009-09-243071.
562	32.	Terrier B, Joly F, Vazquez T, Benech P, Rosenzwajg M, Carpentier W, et al.
563		Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in
564		hepatitis C virus infection-related autoimmunity. J Immunol 2011 ;187(12):6550-63
565		doi 10.4049/jimmunol.1102022.
566	33.	Gies V, Guffroy A, Danion F, Billaud P, Keime C, Fauny JD, et al. B cells
567		differentiate in human thymus and express AIRE. J Allergy Clin Immunol
568		2017 :139(3):1049-52 e12 doi 10.1016/i.jaci.2016.09.044.
569	34.	Yamano T, Nedijc J, Hinterberger M, Steinert M, Koser S, Pinto S, <i>et al</i> , Thymic B
570	-	Cells Are Licensed to Present Self Antigens for Central T Cell Tolerance Induction.
571		Immunity 2015 :42(6):1048-61 doi 10.1016/i.immuni.2015.05.013.
572	35.	Hubert FX, Kinkel SA, Webster KE, Cannon P, Crewther PE, Proeitto AI, et al. A
573		specific anti-Aire antibody reveals aire expression is restricted to medullary thymic
574		epithelial cells and not expressed in periphery. J Immunol 2008 :180(6):3824-32 doi
575		10 4049/iimmunol 180 6 3824
576	36.	Mathis D. Benoist C. Aire, Annu Rey Immunol 2009 :27:287-312 doi
577	001	10.1146/annurev.immunol.25.022106.141532.
578	37.	Fergusson JR, Morgan MD, Bruchard M, Huitema L, Heesters BA, van Unen V, et al.
579		Maturing Human CD127+ CCR7+ PDL1+ Dendritic Cells Express AIRE in the
580		Absence of Tissue Restricted Antigens. Front Immunol 2018 :9:2902 doi
581		10.3389/fimmu.2018.02902.
582	38.	Rubtsova K, Rubtsov AV, Thurman JM, Mennona JM, Kappler JW, Marrack P, B
583		cells expressing the transcription factor T-bet drive lupus-like autoimmunity. J Clin
584		Invest 2017 :127(4):1392-404 doi 10.1172/JCI91250.
585	39.	Phalke S. Rivera-Correa J. Jenkins D. Flores Castro D. Giannopoulou E. Pernis AB.
586		Molecular mechanisms controlling age-associated B cells in autoimmunity. Immunol
587		Rev 2022 :307(1):79-100 doi 10.1111/imr.13068.
588	40.	Melo-Lima BL, Poras I, Passos GA, Carosella ED, Donadi EA, Moreau P. The
589		Autoimmune Regulator (Aire) transactivates HLA-G gene expression in thymic
590		epithelial cells. Immunology 2019 :158(2):121-35 doi 10.1111/imm.13099.
591	41.	Gerber PP. Duncan LM. Greenwood EJ. Marelli S. Naamati A. Teixeira-Silva A. <i>et</i>
592		al. A protease-activatable luminescent biosensor and reporter cell line for authentic
593		SARS-CoV-2 infection. PLoS Pathog 2022 :18(2):e1010265 doi
594		10.1371/iournal.ppat.1010265.
595	42.	Baang JH. Smith C. Mirabelli C. Valesano AL, Manthei DM, Bachman MA, et al.
596		Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an
597		Immunocompromised Patient, J Infect Dis 2021 :223(1):23-7 doi
598		10.1093/infdis/jiaa666.
599	43.	Buckland MS, Galloway JB, Fhogartaigh CN, Meredith L, Provine NM, Bloor S, et
600		<i>al.</i> Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a
601		case report Nat Commun 2020 :11(1):6385 doi 10.1038/s/11/67.020.10761.2
001		case report. That Commun 2020, $rr(1)$, 0.0505 up $rr(10.050/5+1+07-020-1570)$ -2.

603 Figure Legends

604

605 Figure 1. Single cell transcriptional signature of ABCs. Magnetically enriched B cells 606 from PBMCs were analysed through droplet-based single cell RNA sequencing technology 607 (n = 52402). a-c. UMAPs of cells from all individuals coloured by (a) annotated Louvain 608 clusters, (b) health condition (HC, healthy controls; ICB, immune-checkpoint blockade 609 treated cancer patients; IEI CTLA-4/NFKB1, inborn errors of immunity, CTLA-4 and NFKB1 610 mutants respectively; SLE, systemic lupus erythematosus patients), and (c) gender. Dots 611 represent a single cell. d. Proportion of total cells from each health condition belonging to 612 each cluster, clusters coloured as indicated. e. Expression of 46 genes in each B cell cluster 613 which define the different subpopulations. Dot size represents proportion of cells within a 614 cluster expressing the indicated gene and colours represent the average expression level. f. 615 Heatmap representing scaled expression values of genes associated with antigen uptake, 616 processing and class-II presentation in each cluster. g. Gene ontology enrichment analysis 617 of biological processes associated with upregulated genes in classical ABCs. GO terms with 618 highest fold enrichments are ranked by -log (P value). Dot size is proportional to the fold 619 enrichment.

620

621 Figure 2. Classical ABC expression of AIRE and AIRE target genes. a. Volcano plot 622 displaying the differentially expressed genes in ABCs compared to other B cell clusters. 623 Upregulated genes associated with antigen uptake, processing and MHC class II 624 presentation are labelled. AIRE gene is coloured in green. b. UMAP of all B cells coloured 625 by kernel density estimation of AIRE expression level across all identified B cell subsets. 626 UMAP showing the different B cell clusters inset. c. Percentage of cells which are AIRE⁺ in 627 each cluster. d. Violin plot comparing expression score of tissue restricted antigens (gene 628 set from Yamano et al) in AIRE expressing cells and all other cells. Statistical testing via 629 Wilcoxon rank sum test.

630

631 Figure 3. Correlation between frequency of ABCs and neutralising antibody response

to COVID-19 vaccination. a. Cohort details. Samples were collected at days 0, 8, 21 and 105 after the 2nd dose of BNT162b2 vaccine (healthy controls (HC), grey; patients with rare inborn errors of immunity (IEI): NFKB1 red, CTLA-4 and unclassified orange; patients treated with ICB, blue). b. Representative FACS contour plots of CD21^bCD11c⁺ ABCs in CD19 B cells. c. Frequencies of B cells within total lymphocytes and frequencies ABCs within total B cells, at day 0. d. Neutralising antibody titres at 50% inhibition (NT₅₀) against wildtype SARS-CoV-2 at indicated timepoints after 2nd vaccine dose. The limit of detection of

639 the assay is indicated (grey dotted line at $NT_{50} = 20$), and an arbitrary threshold at the 640 highest NT_{50} from the HC group at day 0 (brown dashed line). **e**. Correlations between 641 frequencies of ABCs amongst B cells at day 0 and $NT_{50}s$ at days 8, 21 and 105. f. 642 Frequencies of ABCs amongst CD19⁺ B cells for individuals above and below the arbitrary 643 threshold indicated in panel d at day 105. Where specified, differences between groups 644 were determined using two-tailed non-parametric Mann Whitney tests. Spearman's rank correlation coefficients (rho) are shown, together with indicative linear regression lines plus, 645 646 c-f each point represents one individual.

647

648 Figure 4. Correlation between frequency of RBD-specific B cells and neutralising 649 antibody response to COVID-19 vaccination. a. Representative flow cytometry plots 650 displaying RBD-specific B cell populations amongst total CD19⁺ B cells for different study 651 groups 0, 8, 21 and 105 days (D0, D8, D21 and D105) after the second dose of BNT162b2 652 vaccine. **b.** Frequencies of RBD-specific B cells amongst all CD19⁺ B cells in HC, IEI and 653 ICB patients at days 0, 8, 21 and 105. Each dot represents a single individual (healthy 654 controls (HC), grey; patients with rare inborn errors of immunity (IEI): (NFKB1) red, (CTLA-4 655 and unclassified) orange; patients treated with ICB, blue). c. Correlations between 656 frequencies of RBD-specific B cells amongst all CD19+ B cells at day 0 and NT₅₀s at days 8, 657 21 and 105. d. Correlations between frequencies of ABCs amongst B cells at day 0 and 658 frequencies of RBD-specific B cells at days 8, 21 and 105. e. UMAP projection of total B 659 cells from all donors at all time points displaying memory B cell (MBCs, purple) and 660 plasmablast (PBs, green) populations. f. RBD-specific B cells with MBC (purple) or PB 661 (green) phenotype are shown at days 0, 8, 21 and 105 (columns) for HC (top), IEI (middle) 662 and ICB (bottom) groups. g. Kinetics of RBD-binding cell frequencies amongst MBCs or 663 PBs. Samples with no detectable levels of RBD-specific cells are plotted at an arbitrary value of 10⁻⁴ in (B) and 10⁻³ in (G). Where specified, statistical significance between groups 664 665 was determined using one-way ANOVA (G). P values for panel B are shown in 666 Supplementary Fig. 5. Spearman's rank correlation coefficients (rho) are shown, together 667 with indicative linear regression lines where appropriate.

669 Supplemental Figures and Tables

670 Supplementary Figure 1. Age-associated B cells converge transcriptionally amongst 671 individuals despite their disparate aetiology. a. Magnetically enriched B cells from 672 PBMCs were labelled using barcode featuring and analysed through droplet-based single 673 cell RNA sequencing technology. Expression of surface protein CD11c against CD21 in all B 674 cells. b. Violin plots of CD21 and CD11c surface protein expression in ABCs versus other B 675 cells with CLR-normalised expression values. Statistical testing via Wilcoxon rank sum test 676 with Bonferroni correction. c. UMAPs of total B cells per health condition coloured by 677 annotated clusters (HC, healthy controls; ICB, immune-checkpoint blockade treated patients; 678 IEI CTLA-4/NFKB1, immune errors of immunity, CTLA-4 and NFKB1 mutants respectively; 679 SLE, systemic lupus erythematosus patients). d. Number of samples from each gender, 680 coloured as indicated, in each health condition group. e. Clusters, with percentages of cells 681 from each gender coloured as indicated. f. Clusters, with percentages of cells from each 682 health condition coloured as indicated. Dots represent a single cell (a-c).

683

Supplementary Figure 2. Class-I related genes expression within the different B cell
 clusters. Heatmap representing scaled expression values of genes associated with antigen
 uptake, processing and class-I presentation in each cluster.

687

588 Supplementary Figure 3. Classical age-associated B cells upregulate AIRE in different 589 health conditions. a. UMAP of total B cells showing AIRE+ cells coloured by density of 590 expression. b. UMAPs of total B cells per health condition coloured by kernel density 591 estimation of AIRE expression level (HC, healthy controls; ICB, immune-checkpoint 592 blockade treated patients; IEI CTLA-4/NFKB1, immune errors of immunity, CTLA-4 and 593 NFKB1 mutants respectively; SLE, systemic lupus erythematosus patients).

694

695 Supplementary Figure 4. Decline of the neutralisation capacity after second dose of 696 BNT162b2 vaccine. a. Gating strategy to identify age-associated B cell (ABCs, 697 SingletsLiveCD3-CD19+CD21-CD11+) subset from total B cell population (CD19+). b. IgG 698 end-point titres specific to the spike (S), receptor-binding domain (RBD) and nucleocapsid 699 (NCP) proteins of SARS-CoV2 at day 21 after the second dose of BNT162b2 vaccine. c. 700 Neutralising antibody titres at 50% inhibition (NT₅₀) against wildtype SARS-CoV-2 at 701 indicated timepoints after 2nd dose of BNT162b2 vaccine (healthy controls (HC), grey; 702 patients with rare inborn errors of immunity (IEI): (NFKB1) red, (CTLA-4 and unclassified) 703 orange; patients treated with ICB, blue). The limit of detection of the assays is shown (grey

dotted line at $NT_{50} = 20$). Where specified, statistical significance between groups was determined using 2-way ANOVA with Tukey's multiple comparisons test.

706 Supplementary Figure 5. Accumulation of age-associated B cells impairs humoral 707 responses to COVID-19 vaccination. a. Gating strategy to identify RBD-specific B cell 708 (SingletsLiveStreptavidinBV711-CD19+RBDAF488+RBDAF647+) subset after the second 709 dose of BNT162b2 vaccine. b. Two-way ANOVA with Tukey's multiple comparisons test for 710 statistical analysis of RBD-binding B cells amongst groups. P values are indicated. c. 711 Multiple variable dot plots showing Spearman correlations between RBD-specific B cells and 712 NT₅₀ at days 8, 21 and 105 after the second dose of BNT162b2 vaccine. Dot size represents 713 ABC frequency per individual. d. Correlation matrix using Spearman's rank correlation 714 amongst ABC and B cell frequencies at day 0; and RBD frequencies and NT₅₀ values at 715 days 0, 8, 21 and 105 for the second dose of BNT162b2 vaccine. Data include all samples 716 enrolled in the study; Rho values are shown per correlation.

717

718 Supplementary Table 1 – Differentially expressed genes related to Figure 1e

Supplementary Table 2 – Top 20 biological processes from the gene ontology
 enrichment analysis

721 Supplementary Table 3 – Differentially expressed genes related to Figure 2a

722 Supplementary Table 4 – Characteristics of Inborn Errors of Immunity (IEI) patients

723 and Immune Checkpoint blockade treated (ICB) patients

724 Supplementary Table 5 – Flow cytometry antibodies details

725

726 Acknowledgements

This work was funded by the MRC (grant ref. MC_UU_00025/12), the Medical Research Foundation (MRF-057-0002-RG-THAV-C0798) and The Evelyn Trust (grant number 20/40).

- 729 NM was supported by the MRC (CSF ref. MR/P008801/1 to NJM), NHSBT (grant ref.
- 730 WPA15-02 to NJM) and Addenbrooke's Charitable Trust (grant ref. 900239 to NJM). The

authors thank the Flow Cytometry Services provided by Lucia Pereira Giraldez at the MRC-

- 732 Toxicology Unit, University of Cambridge and Katarzyna Kania from CRUK-CI-Genomics for
- advice on single cell RNA sequencing experiments.

734

735 **Competing interest**

The authors declare no competing financial interests.

737

738 Corresponding Authors

- 739 Correspondence and requests for materials should be addressed to James Thaventhiran
- 740 (jedt2@cam.ac.uk) and Juan Carlos Yam-Puc (jcy28@cam.ac.uk).

742 CITIID-NIHR BioResource COVID-19 Collaboration

Stephen Baker^{2,6}, John Bradley^{1,3,6,11,15}, Patrick Chinnery^{3,23,24}, Daniel Cooper^{11, 25}, 743 Gordon Dougan^{2,6}, Ian Goodfellow⁷, Ravindra Gupta^{2,6,13,16}, Nathalie Kingston^{3,4}, Paul J. 744 Lehner^{2,6,13}, Paul A. Lyons^{2,6}, Nicholas J. Matheson^{2,6,13,33}, Caroline Saunders⁹, Kenneth G. 745 C. Smith^{2,6}, Charlotte Summers^{6,12,26}, James Thaventhiran¹⁹, M. Estee Torok^{6,13,14}, Mark R. 746 Toshner^{6,8,26}, Michael P. Weekes^{2,6,13,34}, Gisele Alvio⁹, Sharon Baker⁹, Areti Bermperi⁹, Karen 747 748 Brookes⁹, Ashlea Bucke, Jo Calder, Laura Canna, Cherry Crucusio, Isabel Cruz⁹, Ranalie de Jesus⁹, Katie Dempsey⁹, Giovanni Di Stephano⁹, Jason Domingo⁹, Anne Elmer⁹, Julie 749 Harris, Sarah Hewitt, Heather Jones⁹, Sherly Jose⁹, Jane Kennet, Yvonne King, Jenny 750 751 Kourampa⁹, Emily Li, Caroline McMahon⁹, Anne Meadows, Vivien Mendoza⁹, Criona 752 O'Brien, Charmain Ocaya⁹, Ciro Pasquale⁹, Marlyn Perales⁹, Jane Price, Rebecca Rastall, 753 Carla Ribeiro⁹, Jane Rowlands, Valentina Ruffolo, Hugo Tordesillas, Phoebe Vargas⁹, Bensi Vergese⁹, Laura Watson⁹, Jieniean Worsley⁹, Julie-Ann Zerrudo⁹, Laura Bergamashi^{2,6}, 754 755 Ariana Betancourt, Georgie Bower, Ben Bullman, Chiara Cossetti, Aloka De Sa, Benjamin J. 756 Dunmore, Maddie Epping, Stuart Fawke, Stefan Gräf^{3,6}, Richard Grenfell, Andrew Hinch, Josh Hodgson, Christopher Huang, Oisin Huhn, Kelvin Hunter^{2,6}, Isobel Jarvis, Emma 757 758 Jones, Maša Josipović, Ekaterina Legchenko, Daniel Lewis, Joe Marsden, Jennifer Martin, Federica Mescia^{2,6}, Ciara O'Donnell, Ommar Omarjee, Marianne Perera, Linda Pointon, 759 760 Nicole Pond, Nathan Richoz, Nika Romashova, Natalia Savoinykh, Rahul Sharma, Joy Shih, 761 Mateusz Strezlecki, Rachel Sutcliffe, Tobias Tilly, Zhen Tong, Carmen Treacy, Lori Turner, Jennifer Wood, Marta Wylot, John Allison^{3,4}, Heather Biggs^{3,18}, John R. Bradley^{1,3,6,11,15}, 762 Helen Butcher^{3,5}, Daniela Caputo^{3,5}, Matt Chandler^{3,5}, Patrick Chinnery^{3,23,24}, Debbie 763 764 Clapham-Riley^{3,5}, Eleanor Dewhurst^{3,5}, Christian Fernandez^{3,4}, Anita Furlong^{3,5}, Barbara Graves^{3,5}, Jennifer Gray^{3,5}, Sabine Hein^{3,5}, Tasmin Ivers^{3,5}, Emma Le Gresley^{3,5}, Rachel 765 Linger^{3,5}, Mary Kasanicki^{3,11}, Rebecca King^{3,5}, Nathalie Kingston^{3,4}, Sarah Meloy^{3,5}, Alexei 766 Moulton^{3,5}, Francesca Muldoon^{3,5}, Nigel Ovington^{3,4}, Sofia Papadia^{3,5}, Christopher J. 767 768 Penkett^{3,4}, Isabel Phelan^{3,5}, Venkatesh Ranganath^{3,4}, Roxana Paraschiv^{3,4}, Abigail Sage^{3,5}, Jennifer Sambrook^{3,4}, Ingrid Scholtes^{3,5}, Katherine Schon^{3,17,18}, Hannah Stark^{3,5}, Kathleen E. 769 Stirrups^{3,4}, Paul Townsend^{3,4}, Neil Walker^{3,4}, Jennifer Webster^{3,5}, Mayurun Selvan³⁵, Petra, 770 Polgarova¹², Sarah L. Caddy^{2,6}, Laura G. Caller^{20,21}, Yasmin Chaudhry⁷, Martin D. Curran²², 771 772 Theresa Feltwell⁶, Stewart Fuller²⁰, Iliana Georgana⁷, Grant Hall⁷, William L. Hamilton^{6,13,14}, 773 Myra Hosmillo⁷, Charlotte J. Houldcroft⁶, Rhys Izuagbe⁷, Aminu S. Jahun⁷, Fahad A. Khokhar^{2,6}, Anna G. Kovalenko⁷, Luke W. Meredith⁷, Surendra Parmar²², Malte L. Pinckert⁷. 774 Anna Yakovleva⁷, Emily C. Horner¹⁹, Lucy Booth¹⁹, Alexander Ferreira¹⁹, Rebecca Boston¹⁹, 775 776 Robert Hughes¹⁹, Juan Carlos Yam Puc¹⁹, Nonantzin Beristain-Covarrubias¹⁹, Maria Rust¹⁹,

- 777 Thevinya Gurugama¹⁹, Lihinya Gurugama¹⁹, Thomas Mulroney¹⁹, Sarah Spencer¹⁹, Zhaleh
- 778 Hosseini¹⁹, Kate Williamson¹⁹.
- 779
- ¹NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus,
- 781 Cambridge, UK
- 782 ²Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey
- 783 Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK
- ³NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge
- 785 Biomedical Campus, Cambridge, UK
- ⁴Department of Haematology, School of Clinical Medicine, University of Cambridge,
- 787 Cambridge Biomedical Campus, Cambridge, UK
- ⁵Department of Public Health and Primary Care, School of Clinical Medicine, University of
- 789 Cambridge, Cambridge Biomedical Campus, Cambridge, UK
- ⁶Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge
- 791 Biomedical Campus, Cambridge, UK
- ⁷Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK
- ⁸Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK
- ⁹Cambridge Clinical Research Centre, Addenbrooke's Hospital, Cambridge University
- 795 Hospitals NHS Foundation Trust, Cambridge, UK
- ¹⁰Intensive Care Unit, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK
- ¹¹Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust,
- 798 Cambridge Biomedical Campus, Cambridge, UK
- ¹²Intensive Care Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS
- 800 Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK
- ¹³Department of Infectious Diseases, Addenbrooke's Hospital, Cambridge University NHS
- 802 Hospitals Foundation Trust, Cambridge, UK
- ¹⁴Department of Microbiology, Addenbrooke's Hospital, Cambridge University NHS Hospitals
- 804 Foundation Trust, Cambridge, UK
- ¹⁵Department of Renal Medicine, Addenbrooke's Hospital, Cambridge University Hospitals
- 806 NHS Foundation Trust, Cambridge, UK
- 807 ¹⁶Africa Health Research Institute, Durban, South Africa
- 808 ¹⁷Clinical Genetics, Addenbrooke's Hospital, Cambridge University Hospitals NHS
- 809 Foundation Trust, Cambridge, UK
- ¹⁸Department of Clinical Neurosciences, School of Clinical Medicine, University of
- 811 Cambridge, Cambridge Biomedical Campus, Cambridge, UK
- ¹⁹MRC Toxicology Unit, Gleeson Building, Tennis Court Road, Cambridge, UK

- 813 ²⁰University of Cambridge, Cambridge, UK
- 814 ²¹The Francis Crick Institute, London, UK
- ²²Public Health England, Clinical Microbiology and Public Health Laboratory, Cambridge, UK
- 816 ²³Department of Clinical Neurosciences, School of Clinical Medicine, University of
- 817 Cambridge, Cambridge Biomedical Campus, Cambridge, UK
- 818 ²⁴Medical Research Council Mitochondrial Biology Unit, Cambridge Biomedical Campus,
- 819 Cambridge, UK
- 820 ²⁵Global and Tropical Health Division, Menzies School of Heath Research and Charles
- 821 Darwin University, Darwin, Northern Territory, Australia
- ²⁶Heart and Lung Research Institute, Cambridge Biomedical Campus, Cambridge, UK
- 823 ²⁷Department of Rheumatology, Addenbrooke's Hospital, Cambridge University Hospitals
- 824 NHS Foundation Trust, Cambridge, UK
- 825 ²⁸Cambridge Cancer Trials Centre, Addenbrooke's Hospital, Cambridge University Hospitals
- 826 NHS Foundation Trust, Cambridge, UK
- ²⁹Department of Paediatrics, University of Cambridge, Cambridge Biomedical Campus,
- 828 Cambridge, UK
- ³⁰Patient Safety, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation
- 830 Trust, Cambridge, UK
- ³¹Clinical Research Network: Eastern, Addenbrooke's Hospital, Cambridge University
- 832 Hospitals NHS Foundation Trust, Cambridge, UK
- 833 ³²Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge University Hospitals
- 834 NHS Foundation Trust, Cambridge, UK
- 835 ³³NHS Blood and Transplant, Cambridge, UK
- ³⁴Cambridge Institute for Medical Research, Biomedical Campus, Hills Rd, Cambridge UK
- ³⁵ Department of Respiratory Medicine, Cambridge University Hospitals NHS Foundation
- 838 Trust, Cambridge, UK
- 839
- 840

841 Method references

842

Zheng, G.X., et al., Massively parallel digital transcriptional profiling of single cells.
 Nat Commun, 2017. 8: p. 14049.

845 2. Roelli, P., B. Flynn, and G. Gui, Hoohm/CITE-seq-Count: 1.5.0. . Zenodo, 2019.

846 3. Hao, Y., et al., Integrated analysis of multimodal single-cell data. Cell, 2021. 184(13):
847 p. 3573-3587 e29.

4. McCarthy, D.J., et al., Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics, 2017. 33(8): p. 1179-1186.

850 5. Bhamidipati, K., et al., CD52 Is Elevated on B cells of SLE Patients and Regulates B
851 Cell Function. Front Immunol, 2020. 11: p. 626820.

852 6. Ashburner, M., et al., Gene ontology: tool for the unification of biology. The Gene853 Ontology Consortium. Nat Genet, 2000. 25(1): p. 25-9.

854 7. Gene Ontology, C., The Gene Ontology resource: enriching a GOld mine. Nucleic
855 Acids Res, 2021. 49(D1): p. D325-D334.

856 8. Mi, H., et al., PANTHER version 14: more genomes, a new PANTHER GO-slim and 857 improvements in enrichment analysis tools. Nucleic Acids Res, 2019. 47(D1): p. D419-D426.

9. Yamano, T., et al., Thymic B Cells Are Licensed to Present Self Antigens for Central
T Cell Tolerance Induction. Immunity, 2015. 42(6): p. 1048-61.

860 10. Alquicira-Hernandez, J. and J.E. Powell, Nebulosa recovers single cell gene
861 expression signals by kernel density estimation. Bioinformatics, 2021.

Xiong, X., et al., A thermostable, closed SARS-CoV-2 spike protein trimer. Nat Struct
Mol Biol, 2020. 27(10): p. 934-941.

12. Collier, D.A., et al., Age-related immune response heterogeneity to SARS-CoV-2
vaccine BNT162b2. Nature, 2021. 596(7872): p. 417-422.

Stadlbauer, D., et al., SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol
for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol, 2020.
57(1): p. e100.

869 14. Daly, J.L., et al., Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science,
870 2020. 370(6518): p. 861-865.

15. Moore, S.C., et al., Amplicon-Based Detection and Sequencing of SARS-CoV-2 in
Nasopharyngeal Swabs from Patients With COVID-19 and Identification of Deletions in the
Viral Genome That Encode Proteins Involved in Interferon Antagonism. Viruses, 2020.
12(10).

875 16. Patterson, E.I., et al., Methods of Inactivation of SARS-CoV-2 for Downstream
876 Biological Assays. J Infect Dis, 2020. 222(9): p. 1462-1467.

17. Bergamaschi, L., et al., Longitudinal analysis reveals that delayed bystander CD8+ T

cell activation and early immune pathology distinguish severe COVID-19 from mild disease.

879 Immunity, 2021. 54(6): p. 1257-1275 e8.

18. Gerber, P.P., et al., A protease-activatable luminescent biosensor and reporter cell
line for authentic SARS-CoV-2 infection. PLoS Pathog, 2022. 18(2): p. e1010265.

19. Knezevic, I., et al., WHO International Standard for evaluation of the antibody
response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet
Microbe, 2022. 3(3): p. e235-e240.

885 20. Hedhammar, M. and S. Hober, Z(basic)--a novel purification tag for efficient protein
886 recovery. J Chromatogr A, 2007. 1161(1-2): p. 22-8.

Figure 1



to antigen presentation

processes

Co-stimulatory molecule Antigen processing in lysosome

Supplementary Figure 1



Supplementary Figure 2



Figure 2



Supplementary Figure 3



Figure 3



Supplementary Figure 4



Figure 4



60.2

Supplementary Figure 5

